At least one study has demonstrated semaglutide's ability to reduce osteoarthritis in people with obesity, possibly in part due to reductions in both weight and inflammation
Intramuscular (IM) injection, by contrast, delivers medication directly into muscle tissue, which has a different vascular supply and absorption profile
What we have instead are approximate clinical equivalencies based on trial data, prescribing patterns, and provider experience
Moreover, semaglutide has been specifically approved for weight loss in individuals with obesity, marking it as a game-changer in the weight management landscape
Your digestive system suddenly works at a different pace, which can cause temporary discomfort
However, animal studies done with Wegovy suggest that there may be risks to using it